Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC

PHASE4UnknownINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

December 1, 2019

Study Completion Date

December 1, 2020

Conditions
NSCLC
Interventions
DRUG

Anlotinib

Anlotinib which has shown an affirmatory efficacy in ALTER0303 controlled trial as a 3rd-line treatment on advanced NSCLC is a tyrosine kinase inhibitor with a favorable safety profile in phase I trial which mainly targets VEGFR1/2/3, FGFR, PDGFR and c-kit.

DRUG

Docetaxel

a chemotherapy medication used to treat a number of types of cancer.This includes breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer.It may be used by itself or along with other chemotherapy medication.It is given by slow injection into a vein.

DRUG

Carboplatin

Carboplatin is used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It may be used for some types of testicular cancer but cisplatin is generally more effective.

Trial Locations (1)

430000

Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology,, Wuhan

All Listed Sponsors
collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

lead

Tongji Hospital

OTHER